Several Research Avenues Are Available for Improving Response to Immunotherapy in Advanced NSCLC

Tony S.K. Mok, MD, BMSc, FRCPC, FASCO, highlights novel partners and potential new approaches for immunotherapy-based regimens for the treatment of patients with non–small cell lung cancer.

Related Keywords

China ,United States ,Chinese ,Eli Lilly ,Cobo Dols ,Merck Serono ,Roche Genentech ,Tonys Mok ,Bristol Myers Squibb ,Pfizer ,Chinese University Of Hong Kong ,Vertex Pharmaceuticals ,Sanomics Ltd ,International Lung Cancer Congress ,Novartis ,Astrazeneca ,Boehringer Ingelheim ,Chinese Lung Cancer Research Foundation Ltd ,Clinical Oncology ,Chinese University ,Hong Kong ,Annual International Lung Cancer ,Merck Sharp ,Clovis Oncology ,International Association ,Lung Cancer ,Annual International Lung Cancer Congress ,Huntington Beach ,Treating Field ,Garcia Campelo ,D ,